Catheter Precision

What Catheter Precision does

Catheter Precision, Inc. (NYSE American: VTAK) is a US-domiciled, publicly traded medical device company that develops and markets products for cardiac electrophysiology procedures. The company's core medical products are VIVO, a non-invasive 3D cardiac imaging system that uses proprietary inverse-solution algorithms applied to 12-lead ECG and CT/MRI inputs to localize ventricular arrhythmias pre-procedure (with 99.5% accuracy and 27% shorter procedure times in clinical data), and LockeT, a suture retention device for vascular access site closure that achieves 98% hemostasis at 2 hours in clinical studies and enables same-day discharge for catheter sizes up to 27F. Both products hold FDA clearance, and LockeT additionally carries the CE Mark for European sale. The company sells primarily to hospitals and electrophysiology labs through direct sales teams and regional distributors such as FuMedica AG in Switzerland, with named customers including Mater Private Hospital (Ireland), Spitalzentrum Biel (Switzerland), and five South African hospitals.

In March 2026 Catheter Precision completed the acquisition of the remaining 80.02% of Fly Flyte, Inc., giving it 100% ownership of Flyte, an AI-enabled regional air mobility operator running Cirrus Vision Jets under FAA Part 135 certification through subsidiary Ponderosa Air, LLC. Flyte operates short-haul routes along the US East Coast (Maine to Florida following the March 2026 Florida expansion) and has joined the Vaunt operator network to monetize repositioning flights. Revenue streams consist of hardware sales of VIVO and LockeT devices, royalty income from the February 2026 divestiture of atherectomy catheter technologies (1.5%-3% of net sales for ten years plus a 5% equity stake in the acquirer), and aviation charter revenue, with Q1 2026 consolidated revenue of $432,000 (up 200% year-over-year) and a Q1 2026 net loss of $1.7M (improved from $4.0M a year earlier).

The company is undergoing a strategic pivot: in April 2026 management announced it is actively seeking a buyer for the cardiac electrophysiology business in order to focus on the Flyte aviation platform, while concurrently strengthening the balance sheet via up to $36.5M of strategic institutional financing (February 2026), expanding the IP portfolio with 11 newly allowed patents (June 2026), and taking a 7.5% strategic stake in Volato Group, Inc. to align with the Parslee / Volato AI aviation software ecosystem. Catheter Precision is led by founder-CEO David Jenkins (former CEO of EP MedSystems and Arrhythmia Research Technology) and CFO Phil Anderson, and is headquartered in Fort Mill, South Carolina, with an EU authorized representative in Münster, Germany.

Name

Catheter Precision

Legal name

Catheter Precision Inc.

Website

https://catheterprecision.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Catheter Precision (NYSE American: VTAK) develops FDA-cleared cardiac electrophysiology devices, including the VIVO non-invasive 3D cardiac imaging system and LockeT suture retention device, and operates Flyte, an AI-enabled regional air mobility subsidiary using Cirrus Vision Jets under FAA Part 135 certification.

Ownership category

akta.pro rank

Product category

Cardiac Electrophysiology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

akta.pro secondary industry

Electrophysiology (Heart Rhythm) (HLAKABAC)

Keywords

• Cardiac electrophysiology devices
• 3D cardiac imaging
• Vascular closure devices
• Regional air mobility
• Arrhythmia localization

Headquarters

HQ city

Fort Mill

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Medical Device Sales: Revenue from sales of LockeT suture retention devices and VIVO imaging systems to hospitals and electrophysiology labs in the US and internationally (Europe, South Africa, Switzerland, Ireland). Q1 2026 revenue of $432,000 representing 200% year-over-year growth.
2. Royalty Income: Ten-year royalty payments of 1.5% to 3% on net sales from the divestiture of atherectomy catheter technologies, plus 5% equity stake in acquiring company with anti-dilution protection.
3. Aviation Services: Revenue from Flyte's regional air mobility platform operating Cirrus Vision Jets on short-haul routes. Flyte achieved $200,000 monthly revenue run rate within 22 days of post-acquisition operations in March 2026. Soft launch in Florida generated over $160,000 in inbound flight bookings on a single aircraft.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Catheter Precision develops, manufactures, and markets medical devices for cardiac electrophysiology procedures, including the VIVO non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization and the LockeT suture retention device for vascular closure after catheter procedures. Through its wholly owned Flyte subsidiary, the company also operates AI-enabled regional air mobility services using Cirrus Vision Jets on East Coast short-haul routes.

Product overview

Catheter Precision operates as a dual-engine growth platform combining clinically validated medical devices with technology-enabled aviation infrastructure. The medical device segment centers on two FDA-cleared/CE Marked products: VIVO, a non-invasive 3D cardiac imaging system using proprietary algorithms for pre-procedure arrhythmia localization, and LockeT, a suture retention device for access site closure enabling same-day discharge. The company also operates Flyte, a regional air mobility subsidiary utilizing Cirrus Vision Jets, which was fully acquired in March 2026. The portfolio spans electrophysiology procedures, cardiac imaging, and private aviation services, supported by a library of over 50 patents.

Differentiator

Problem solved

Functional benefit

Brands

• VIVO: Non-invasive 3D cardiac imaging system for pre-procedure arrhythmia localization
• LockeT
• Ponderosa Air
• Flyte

Products and services

• VIVO Non-Invasive 3D Cardiac Imaging System Non-invasive 3D cardiac imaging system that uses standard 12-lead ECG recordings combined with CT/MRI imaging and proprietary inverse-solution algorithms to create patient-specific 3D heart models with activation maps for pre-procedure localization of ventricular arrhythmias. For electrophysiology labs and hospitals performing cardiac catheter ablation procedures.
• LockeT Suture Retention Device External compression vascular closure device used with a figure-of-eight suture technique to achieve hemostasis after cardiac catheter access procedures. Compatible with catheter sizes up to 27F and enables same-day hospital discharge with 98% hemostasis success at 2 hours in clinical studies. For hospitals and electrophysiology labs performing catheter-based procedures.
• Flyte Regional Air Mobility Service AI-enabled regional air mobility service operating FAA Part 135 certified flights using Cirrus Vision Jets on high-frequency short-haul routes along the U.S. East Coast (Maine to Florida), through wholly owned subsidiary Ponderosa Air, LLC. For high-net-worth individuals, corporate hospitality groups, and professional athletes.

Quantifiable outcome

• 27% shorter procedure time with VIVO system
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• GSE WorldwidecoreGTM or Marketing Partner · 22 June 2026Flyte partnered with sports agency GSE Worldwide and PGA TOUR professional Emiliano Grillo, debuting at the 2026 U.S. Open Championship. The partnership showcases Flyte's fleet of Cirrus Vision Jets as a regional travel alternative for professional athletes with demanding multi-market schedules. Positions Flyte for continued expansion into professional sports.
• Vaunt (Volato Group)coreChannel Partner/ Reseller/ Distributor · 11 June 2026Flyte joined the Vaunt operator network, a membership-based private aviation platform owned by Volato Group, Inc. The partnership allows Flyte's fleet of Cirrus Vision Jets to access Vaunt's expanding member base, creating new opportunities to monetize repositioning flights and increase aircraft utilization. Vaunt reported $3.6M annual recurring revenue with 162% YoY growth.
• Volato Group, Inc.coreStrategic or Co-development Partner · 8 June 2026Flyte (subsidiary of Catheter Precision) acquired approximately 2.9 million shares representing a 7.5% ownership stake in Volato Group, becoming its largest shareholder. The strategic investment aims to explore potential future collaboration across private aviation platforms and create long-term shareholder value for both organizations. Volato operates Parslee AI software platform and is developing Volato AI for aviation.
• Creatd, Inc.coreStrategic or Co-development Partner · 17 February 2026Catheter Precision acquired remaining 80.02% equity interest in Fly Flyte, Inc. from Creatd, Inc., achieving 100% ownership. Transaction valued at approximately $6 million in cash and nearly $6 million in Convertible Preferred Stock. Flyte became wholly owned subsidiary with financial results consolidated into VTAK's statements.
• FuMedica AGcoreChannel Partner/ Reseller/ Distributor · 16 October 2025Swiss medical distributor FuMedica AG distributes LockeT suture retention device in Switzerland through partnership agreement. Initial procedures performed at Spitalzentrum Biel. Partnership aims to enhance cardiac procedure outcomes in Swiss hospitals.
• PeriKard, LLCminorStrategic or Co-development Partner · 15 January 2025Catheter Precision announced a definitive agreement to acquire PeriKard, LLC, expanding its cardiac electrophysiology portfolio.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Acutus Medical: Acutus Medical develops cardiac electrophysiology mapping and ablation technologies, directly comparable to Catheter Precision's VIVO imaging system in the ventricular arrhythmia pre-procedure planning category.
• Haemonetics: Haemonetics' Vascade vascular closure device directly competes with LockeT in the post-catheter access site closure market for both electrophysiology and interventional cardiology procedures.
• Volato Group: Volato operates the Vaunt membership-based private aviation platform and is both a strategic partner (7.5% Catheter Precision stake) and a directly comparable regional private aviation operator using similar aircraft classes.

Broad incumbents

• Boston Scientific: Boston Scientific is a major incumbent in cardiac electrophysiology through its EP and cardiac surgery franchises, providing direct competition and representing a likely strategic acquirer for Catheter Precision's EP portfolio.
• Abbott: Abbott competes in both cardiac EP (mapping/ablation) and vascular closure (Perclose, StarClose), making it directly comparable across Catheter Precision's two medical device product lines and a potential strategic acquirer.
• Biosense Webster (Johnson & Johnson): Biosense Webster is the dominant incumbent in cardiac electrophysiology mapping and ablation (CARTO 3D system), making it the most significant competitor to VIVO in pre-procedure arrhythmia localization.
• Terumo Medical: Terumo's Angio-Seal is one of the leading vascular closure devices globally, competing with LockeT across catheter-based procedures in hospitals and electrophysiology labs.
• Medtronic: Medtronic is a broad incumbent in cardiac diagnostics, EP, and structural heart, with cardiac diagnostic and monitoring capabilities that overlap with VIVO's pre-procedure imaging franchise.
• Wheels Up: Wheels Up is an established private aviation membership platform operating regional and national routes, comparable to Flyte's positioning in short-haul, high-frequency regional private aviation.

Emerging players

• CathVision: CathVision is an emerging player in cardiac EP signal acquisition and mapping technology, comparable to VIVO as an innovation-driven EP imaging player targeting the same electrophysiology lab customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/catheterinc
• LinkedInlinkedin.com/company/catheterprecision

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catheter Precision